Identification

Name
Mycophenolic acid
Accession Number
DB01024  (APRD01603, EXPT02208)
Type
Small Molecule
Groups
Approved
Description

Mycophenolic acid is an an immunosuppresant drug and potent anti-proliferative, and can be used in place of the older anti-proliferative azathioprine. It is usually used as part of triple therapy including a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. It is also useful in research for the selection of animal cells that express the E. coli gene coding for XGPRT (xanthine guanine phosphoribosyltransferase).

Structure
Thumb
Synonyms
  • (e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
  • Acide mycophenolique
  • Acido micofenolico
  • Acidum mycophenolicum
  • Micofenolico acido
  • Mycophenolate
  • Mycophenolsäure
External IDs
68618 / NSC-129185
Product Ingredients
IngredientUNIICASInChI Key
Mycophenolate sodiumWX877SQI1G 37415-62-6DOZYTHNHLLSNIK-JOKMOOFLSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MyforticTablet, delayed release180 mg/1OralNovartis2004-02-27Not applicableUs
MyforticTablet, delayed release180 mgOralNovartis2005-02-11Not applicableCanada
MyforticTablet, delayed release360 mg/1OralNovartis2004-02-27Not applicableUs00078 0386 66 nlmimage10 a116d0a6
MyforticTablet, delayed release360 mgOralNovartis2005-02-11Not applicableCanada
MyforticTablet, delayed release180 mg/1OralAvera Mc Kennan Hospital2015-03-01Not applicableUs
Sandoz Mycophenolic AcidTablet, delayed release360 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Mycophenolic AcidTablet, delayed release180 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-mycophenolic AcidTablet, delayed release180 mgOralApotex Corporation2014-07-02Not applicableCanada
Apo-mycophenolic AcidTablet, delayed release360 mgOralApotex Corporation2014-07-02Not applicableCanada
Mycophenolic AcidTablet, delayed release180 mg/1OralAmerincan Health Packaging2015-01-15Not applicableUs
Mycophenolic AcidTablet, delayed release360 mg/1OralAccord Healthcare Limited2017-09-06Not applicableUs
Mycophenolic AcidTablet, delayed release360 mg/1OralGolden State Medical Supply2014-10-13Not applicableUs60505 2966 07 nlmimage10 923ec936
Mycophenolic AcidTablet, delayed release360 mg/1OralMylan Pharmaceuticals2014-01-08Not applicableUs
Mycophenolic AcidTablet, delayed release180 mg/1OralApotex Corporation2012-08-21Not applicableUs
Mycophenolic AcidTablet, delayed release360 mg/1OralAmerincan Health Packaging2015-01-15Not applicableUs
Mycophenolic AcidTablet, delayed release180 mg/1OralAccord Healthcare Limited2017-09-06Not applicableUs
Mycophenolic AcidTablet, delayed release180 mg/1OralMylan Institutional2014-01-20Not applicableUs
International/Other Brands
Melbex
Categories
UNII
HU9DX48N0T
CAS number
24280-93-1
Weight
Average: 320.3371
Monoisotopic: 320.125988372
Chemical Formula
C17H20O6
InChI Key
HPNSFSBZBAHARI-RUDMXATFSA-N
InChI
InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+
IUPAC Name
(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
SMILES
COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C

Pharmacology

Indication

For the prophylaxis of organ rejection in patients receiving allogeneic renal transplants, administered in combination with cyclosporine and corticosteroids.

Structured Indications
Pharmacodynamics

Mycophenolic acid is an antibiotic substance derived from Penicillium stoloniferum. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites.

Mechanism of action

Mycophenolic acid is a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Because T- and B-lymphocytes are critically dependent for their proliferation on de novo synthesis of purines, whereas other cell types can utilize salvage pathways, mycophenolic acid has potent cytostatic effects on lymphocytes. Mycophenolic acid inhibits proliferative responses of T- and B-lymphocytes to both mitogenic and allospecific stimulation. Addition of guanosine or deoxyguanosine reverses the cytostatic effects of mycophenolic acid on lymphocytes. Mycophenolic acid also suppresses antibody formation by B-lymphocytes. Mycophenolic acid prevents the glycosylation of lymphocyte and monocyte glycoproteins that are involved in intercellular adhesion to endothelial cells and may inhibit recruitment of leukocytes into sites of inflammation and graft rejection.

TargetActionsOrganism
AInosine-5'-monophosphate dehydrogenase 2
inhibitor
Human
AInosine-5'-monophosphate dehydrogenase 1
inhibitor
Human
Absorption

Bioavailability following oral administration of Myfortic delayed-release tablet ranges from 70-95%

Volume of distribution
  • 54 ± 25 L
Protein binding

>98%

Metabolism

Mycophenolic acid is metabolized mainly by glucuronyl transferase to glucuronidated metabolites, predominantly the phenolic glucuronide, mycophenolic acid glucuronide (MPAG). MPAG does not manifest pharmacological activity. The acyl glucuronide minor metabolite has pharmacological activity similar to mycophenolic acid. The AUC ratio of Mycophenolic acid:MPAG:acyl glucuronide is approximately 1:24:0.28 at steady state.

Route of elimination
Not Available
Half life

The mean elimination half-life for mycophenolic acid ranges from 8-16 hours, while that of the MPAG metabolite ranges from 13-17 hours.

Clearance
  • 140 +/- 30 mL/min [Stable renal transplant patients]
Toxicity

Oral (LD50): Acute: 352 mg/kg [Rat], 1000 mg/kg [Mouse], and >6000 mg/kg [Rabbit]. Possible signs and symptoms of acute overdose could include the following: hematological abnormalities such as leukopenia and neutropenia, and gastrointestinal symptoms such as abdominal pain, diarrhea, nausea and vomiting, and dyspepsia.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Mycophenolic Acid Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with 5-androstenedione.Experimental, Illicit
AbciximabMycophenolic acid may increase the anticoagulant activities of Abciximab.Approved
AcebutololMycophenolic acid may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Aceclofenac.Approved
AcemetacinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Acemetacin.Experimental
AcenocoumarolMycophenolic acid may increase the anticoagulant activities of Acenocoumarol.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Mycophenolic acid.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Mycophenolic acid.Experimental
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Mycophenolic acid.Approved, Vet Approved
AclarubicinMycophenolic acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Mycophenolic acid.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Alendronic acid.Approved
AlgeldrateAlgeldrate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AliskirenMycophenolic acid may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlmagateAlmagate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlmasilateAlmasilate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Alminoprofen.Experimental
AloglutamolAloglutamol can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlprenololMycophenolic acid may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Mycophenolic acid.Approved, Investigational
AluminiumAluminium can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Amcinonide.Approved
AmdinocillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Amdinocillin resulting in a loss in efficacy.Withdrawn
AmikacinMycophenolic acid may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideMycophenolic acid may decrease the antihypertensive activities of Amiloride.Approved
AmoxicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Amoxicillin resulting in a loss in efficacy.Approved, Vet Approved
AmpicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Ampicillin resulting in a loss in efficacy.Approved, Vet Approved
AmrubicinMycophenolic acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodMycophenolic acid may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Anisodamine.Investigational
annamycinMycophenolic acid may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Antipyrine.Approved
Antithrombin III humanMycophenolic acid may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanMycophenolic acid may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Apocynin.Investigational
ApramycinMycophenolic acid may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Apremilast.Approved, Investigational
ArbekacinMycophenolic acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinMycophenolic acid may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanMycophenolic acid may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololMycophenolic acid may decrease the antihypertensive activities of Arotinolol.Approved
AspoxicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Aspoxicillin resulting in a loss in efficacy.Experimental
AtamestaneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Atamestane.Investigational
AtenololMycophenolic acid may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Mycophenolic acid.Approved
AzidocillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Azidocillin resulting in a loss in efficacy.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Mycophenolic acid.Approved
AzlocillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Azlocillin resulting in a loss in efficacy.Approved
BacampicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Bacampicillin resulting in a loss in efficacy.Approved
BalsalazideMycophenolic acid may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Mycophenolic acid.Investigational
BecaplerminMycophenolic acid may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololMycophenolic acid may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinMycophenolic acid may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Mycophenolic acid.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mycophenolic acid.Approved
BenorilateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Benoxaprofen.Withdrawn
Benzathine benzylpenicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Benzathine benzylpenicillin resulting in a loss in efficacy.Approved, Vet Approved
BenzylpenicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Benzylpenicillin resulting in a loss in efficacy.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Benzylpenicilloyl Polylysine resulting in a loss in efficacy.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Mycophenolic acid.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Betamethasone.Approved, Vet Approved
BetaxololMycophenolic acid may decrease the antihypertensive activities of Betaxolol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Mycophenolic acid.Approved, Investigational
BevantololMycophenolic acid may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Mycophenolic acid.Approved, Investigational
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BisoprololMycophenolic acid may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinMycophenolic acid may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololMycophenolic acid may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Mycophenolic acid.Approved
BucillamineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bucillamine.Investigational
BucindololMycophenolic acid may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bufexamac.Experimental
BufuralolMycophenolic acid may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bumadizone.Experimental
BumetanideMycophenolic acid may decrease the diuretic activities of Bumetanide.Approved
BupranololMycophenolic acid may decrease the antihypertensive activities of Bupranolol.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mycophenolic acid.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Mycophenolic acid.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Mycophenolic acid.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Mycophenolic acid.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Carbaspirin calcium.Experimental
CarbenicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Carbenicillin resulting in a loss in efficacy.Approved
Carbenicillin indanylThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Carbenicillin indanyl resulting in a loss in efficacy.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Mycophenolic acid.Approved
CarfecillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Carfecillin resulting in a loss in efficacy.Experimental
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Mycophenolic acid.Approved, Vet Approved, Withdrawn
CarteololMycophenolic acid may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolMycophenolic acid may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Castanospermine.Experimental
CeliprololMycophenolic acid may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinMycophenolic acid may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Mycophenolic acid.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mycophenolic acid.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Mycophenolic acid.Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Mycophenolic acid.Approved
CholestyramineThe serum concentration of Mycophenolic acid can be decreased when it is combined with Cholestyramine.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Mycophenolic acid.Approved
CinoxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Cinoxacin.Approved, Withdrawn
Citric AcidMycophenolic acid may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Mycophenolic acid.Vet Approved
CloranololMycophenolic acid may decrease the antihypertensive activities of Cloranolol.Experimental
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Mycophenolic acid.Approved
CloxacillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Cloxacillin resulting in a loss in efficacy.Approved, Vet Approved
ColesevelamThe serum concentration of Mycophenolic acid can be decreased when it is combined with Colesevelam.Approved
ColestipolThe serum concentration of Mycophenolic acid can be decreased when it is combined with Colestipol.Approved
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Mycophenolic acid.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Cortisone acetate.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Mycophenolic acid.Approved
CurcuminThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Curcumin.Investigational
CyclacillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Cyclacillin resulting in a loss in efficacy.Approved
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Mycophenolic acid.Experimental
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Mycophenolic acid.Approved, Investigational
CyclosporineThe serum concentration of Mycophenolic acid can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Mycophenolic acid.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with D-Limonene.Investigational
Dabigatran etexilateMycophenolic acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinMycophenolic acid may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidMycophenolic acid may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanMycophenolic acid may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinMycophenolic acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Deferasirox.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Mycophenolic acid.Experimental
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Mycophenolic acid.Approved
DesirudinMycophenolic acid may increase the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Mycophenolic acid.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desmopressin.Approved
DesogestrelThe serum concentration of Desogestrel can be decreased when it is combined with Mycophenolic acid.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Mycophenolic acid.Approved
DexlansoprazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Dexlansoprazole.Approved
DexrabeprazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Dexrabeprazole.Experimental
DextranMycophenolic acid may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Mycophenolic acid may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Mycophenolic acid may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Mycophenolic acid may increase the anticoagulant activities of Dextran 75.Approved
DibekacinMycophenolic acid may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Mycophenolic acid.Approved, Vet Approved
DicloxacillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Dicloxacillin resulting in a loss in efficacy.Approved, Vet Approved
DicoumarolMycophenolic acid may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Mycophenolic acid.Approved
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Mycophenolic acid.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Mycophenolic acid.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Mycophenolic acid.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Difluprednate.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Mycophenolic acid.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Mycophenolic acid.Approved
DihydrostreptomycinMycophenolic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Mycophenolic acid.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Mycophenolic acid.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Mycophenolic acid.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mycophenolic acid.Approved, Investigational
DoxorubicinMycophenolic acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneThe serum concentration of Drospirenone can be decreased when it is combined with Mycophenolic acid.Approved
DroxicamThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with E-6201.Investigational
Edetic AcidMycophenolic acid may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanMycophenolic acid may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Mycophenolic acid.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Mycophenolic acid.Approved
EnoxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Enoxacin.Approved
EnoxaparinMycophenolic acid may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Mycophenolic acid.Experimental
EpanololMycophenolic acid may decrease the antihypertensive activities of Epanolol.Experimental
EpicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Epicillin resulting in a loss in efficacy.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Epirizole.Approved
EpirubicinMycophenolic acid may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneMycophenolic acid may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Mycophenolic acid.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mycophenolic acid.Approved
EquileninThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Equilin.Approved
EsmololMycophenolic acid may decrease the antihypertensive activities of Esmolol.Approved
EsomeprazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Mycophenolic acid.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Mycophenolic acid.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Mycophenolic acid.Approved
EstroneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Estrone.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Mycophenolic acid.Approved
Etacrynic acidMycophenolic acid may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Mycophenolic acid.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Mycophenolic acid.Approved
Ethyl biscoumacetateMycophenolic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Mycophenolic acid.Approved
Etidronic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etidronic acid.Approved
EtofenamateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etofenamate.Approved
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Mycophenolic acid.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Mycophenolic acid.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Mycophenolic acid.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Feprazone.Experimental
Ferulic acidMycophenolic acid may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Mycophenolic acid.Approved
FingolimodMycophenolic acid may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Mycophenolic acid.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with fluasterone.Investigational
FlucloxacillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Flucloxacillin resulting in a loss in efficacy.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fludrocortisone.Approved
FluindioneMycophenolic acid may increase the anticoagulant activities of Fluindione.Investigational
FlumequineThe serum concentration of Mycophenolic acid can be decreased when it is combined with Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Flumethasone.Approved, Vet Approved
FlunixinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Mycophenolic acid.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Mycophenolic acid.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Mycophenolic acid.Approved, Nutraceutical, Vet Approved
FondaparinuxMycophenolic acid may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumMycophenolic acid may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Mycophenolic acid.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mycophenolic acid.Approved
FramycetinMycophenolic acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideMycophenolic acid may decrease the diuretic activities of Furosemide.Approved, Vet Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Mycophenolic acid.Investigational
GabexateMycophenolic acid may increase the anticoagulant activities of Gabexate.Investigational
GanciclovirThe serum concentration of Ganciclovir can be increased when it is combined with Mycophenolic acid.Approved, Investigational
GarenoxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Garenoxacin.Investigational
GatifloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Mycophenolic acid.Approved, Withdrawn
GemifloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Gemifloxacin.Approved, Investigational
GeneticinMycophenolic acid may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinMycophenolic acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AMycophenolic acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GestodeneThe serum concentration of Gestodene can be decreased when it is combined with Mycophenolic acid.Approved
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Mycophenolic acid.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Mycophenolic acid.Experimental
GPX-150Mycophenolic acid may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Grepafloxacin.Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Guacetisal.Experimental
HaloperidolThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with HE3286.Investigational
HeparinMycophenolic acid may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Mycophenolic acid.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Higenamine.Investigational
HydralazineMycophenolic acid may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mycophenolic acid.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mycophenolic acid.Approved
HydrotalciteHydrotalcite can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Hygromycin BMycophenolic acid may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Icatibant.Approved
IdarubicinMycophenolic acid may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxMycophenolic acid may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Mycophenolic acid.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Mycophenolic acid.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mycophenolic acid.Approved
IndenololMycophenolic acid may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Mycophenolic acid.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Indoprofen.Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Mycophenolic acid.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Mycophenolic acid.Investigational
INNO-206Mycophenolic acid may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Mycophenolic acid.Approved, Investigational
IsavuconazoniumThe serum concentration of Mycophenolic acid can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsepamicinMycophenolic acid may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Istaroxime.Investigational
KanamycinMycophenolic acid may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Mycophenolic acid.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Mycophenolic acid.Approved
LabetalolMycophenolic acid may decrease the antihypertensive activities of Labetalol.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Mycophenolic acid.Experimental
LandiololMycophenolic acid may decrease the antihypertensive activities of Landiolol.Investigational
LansoprazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Lansoprazole.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Mycophenolic acid.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Mycophenolic acid.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Leflunomide.Approved, Investigational
LepirudinMycophenolic acid may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanMycophenolic acid may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololMycophenolic acid may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Levofloxacin.Approved, Investigational
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Mycophenolic acid.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Mycophenolic acid.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Mycophenolic acid.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Mycophenolic acid.Approved
LonazolacThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Mycophenolic acid.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Mycophenolic acid.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Mycophenolic acid.Vet Approved
LynestrenolThe serum concentration of Lynestrenol can be decreased when it is combined with Mycophenolic acid.Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium HydroxideThe serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium salicylateThe serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium SulfateThe serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Mycophenolic acid.Approved
ME-609The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Mycophenolic acid.Approved, Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Mycophenolic acid.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Mycophenolic acid.Approved
MelagatranMycophenolic acid may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Mycophenolic acid.Approved, Vet Approved
MepindololMycophenolic acid may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineMycophenolic acid may increase the nephrotoxic activities of Mesalazine.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Mycophenolic acid.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Metamizole.Withdrawn
MetampicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Metampicillin resulting in a loss in efficacy.Experimental
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Mycophenolic acid.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Mycophenolic acid.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mycophenolic acid.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Methylprednisolone.Approved, Vet Approved
MeticillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Meticillin resulting in a loss in efficacy.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Mycophenolic acid.Experimental
MetipranololMycophenolic acid may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mycophenolic acid.Approved
MetoprololMycophenolic acid may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideMycophenolic acid may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MetronidazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Metronidazole.Approved
MezlocillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Mezlocillin resulting in a loss in efficacy.Approved
MicronomicinMycophenolic acid may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Mycophenolic acid.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Mycophenolic acid.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Mofebutazone.Experimental
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Mycophenolic acid.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mycophenolic acid.Approved, Investigational
NadololMycophenolic acid may decrease the antihypertensive activities of Nadolol.Approved
NadroparinMycophenolic acid may increase the anticoagulant activities of Nadroparin.Approved
NafamostatMycophenolic acid may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NafcillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Nafcillin resulting in a loss in efficacy.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Mycophenolic acid.Approved
Nalidixic AcidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Mycophenolic acid.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Natalizumab.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with NCX 1022.Investigational
NeamineMycophenolic acid may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Nemonoxacin.Investigational
NeomycinMycophenolic acid may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Nepafenac.Approved
NetilmicinMycophenolic acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Nitroaspirin.Investigational
NorelgestrominThe serum concentration of Norelgestromin can be decreased when it is combined with Mycophenolic acid.Approved
NorfloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Norfloxacin.Approved
NorgestimateThe serum concentration of Norgestimate can be decreased when it is combined with Mycophenolic acid.Approved
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Mycophenolic acid.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Mycophenolic acid.Experimental
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mycophenolic acid.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mycophenolic acid.Approved
OlsalazineMycophenolic acid may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Mycophenolic acid.Investigational
OmeprazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Orgotein.Vet Approved
OtamixabanMycophenolic acid may increase the anticoagulant activities of Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Mycophenolic acid.Approved
OxacillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Oxacillin resulting in a loss in efficacy.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Mycophenolic acid.Approved
Oxolinic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Oxolinic acid.Experimental
OxprenololMycophenolic acid may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Oxyphenbutazone.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mycophenolic acid.Approved, Vet Approved
PamidronateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pamidronate.Approved
PantoprazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Pantoprazole.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Paramethasone.Approved
ParomomycinMycophenolic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Parthenolide.Investigational
PazufloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Pazufloxacin.Investigational
PefloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Pefloxacin.Approved
PenamecillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Penamecillin resulting in a loss in efficacy.Experimental
PenbutololMycophenolic acid may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PenimepicyclineThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Penimepicycline resulting in a loss in efficacy.Experimental
Pentosan PolysulfateMycophenolic acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Mycophenolic acid.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Mycophenolic acid.Experimental
PhenindioneMycophenolic acid may increase the anticoagulant activities of Phenindione.Approved
PhenoxymethylpenicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Phenoxymethylpenicillin resulting in a loss in efficacy.Approved, Vet Approved
PhenprocoumonMycophenolic acid may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Mycophenolic acid.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mycophenolic acid.Approved, Investigational
PindololMycophenolic acid may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Pipemidic acid.Experimental
PiperacillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Piperacillin resulting in a loss in efficacy.Approved
PirarubicinMycophenolic acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideMycophenolic acid may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pirfenidone.Investigational
Piromidic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Mycophenolic acid.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pirprofen.Experimental
PivampicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Pivampicillin resulting in a loss in efficacy.Approved
PivmecillinamThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Pivmecillinam resulting in a loss in efficacy.Approved
PlazomicinMycophenolic acid may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinMycophenolic acid may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Mycophenolic acid.Approved
PractololMycophenolic acid may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Mycophenolic acid.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pranoprofen.Experimental
PrasteroneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of Mycophenolic acid can be increased when it is combined with Probenecid.Approved
Procaine benzylpenicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Procaine benzylpenicillin resulting in a loss in efficacy.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Propacetamol.Approved
PropicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Propicillin resulting in a loss in efficacy.Experimental
PropranololMycophenolic acid may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Proquazone.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Mycophenolic acid.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Mycophenolic acid.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Mycophenolic acid.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Mycophenolic acid.Vet Approved
Protein CMycophenolic acid may increase the anticoagulant activities of Protein C.Approved
Protein S humanMycophenolic acid may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeMycophenolic acid may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with PTC299.Investigational
PuromycinMycophenolic acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Mycophenolic acid.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Mycophenolic acid.Approved
RabeprazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Rabeprazole.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Mycophenolic acid.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Mycophenolic acid.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Mycophenolic acid.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Resveratrol.Experimental, Investigational
ReviparinMycophenolic acid may increase the anticoagulant activities of Reviparin.Approved
RibostamycinMycophenolic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifabutinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Mycophenolic acid can be decreased when it is combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Rimexolone.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Mycophenolic acid.Investigational
RisedronateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Risedronate.Approved, Investigational
RivaroxabanMycophenolic acid may increase the anticoagulant activities of Rivaroxaban.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Mycophenolic acid.Approved
RosoxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Rosoxacin.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Mycophenolic acid.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Mycophenolic acid.Approved
RufloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Rufloxacin.Experimental
SabarubicinMycophenolic acid may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Mycophenolic acid.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Mycophenolic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mycophenolic acid.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Mycophenolic acid.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Serrapeptase.Investigational
SevelamerThe serum concentration of Mycophenolic acid can be decreased when it is combined with Sevelamer.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mycophenolic acid.Approved
SisomicinMycophenolic acid may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Sitafloxacin.Experimental
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Mycophenolic acid.Approved
SotalolMycophenolic acid may decrease the antihypertensive activities of Sotalol.Approved
SP1049CMycophenolic acid may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Sparfloxacin.Approved
SpectinomycinMycophenolic acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Mycophenolic acid.Approved
SpironolactoneMycophenolic acid may decrease the antihypertensive activities of Spironolactone.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Mycophenolic acid.Investigational
SRT501The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with SRT501.Investigational
StreptomycinMycophenolic acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinMycophenolic acid may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulbactamThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Sulbactam resulting in a loss in efficacy.Approved
SulbenicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Sulbenicillin resulting in a loss in efficacy.Experimental
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mycophenolic acid.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Mycophenolic acid.Approved
SulodexideMycophenolic acid may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Mycophenolic acid.Investigational
SultamicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Sultamicillin resulting in a loss in efficacy.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Mycophenolic acid.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Suxibuzone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Mycophenolic acid.Approved
TacrolimusMycophenolic acid may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Mycophenolic acid.Approved
TalampicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Talampicillin resulting in a loss in efficacy.Experimental
TalinololMycophenolic acid may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Mycophenolic acid.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Mycophenolic acid.Approved
TazobactamThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Tazobactam resulting in a loss in efficacy.Approved
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Mycophenolic acid.Investigational
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Mycophenolic acid.Approved, Investigational
TemafloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Mycophenolic acid.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Mycophenolic acid.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Teriflunomide.Approved
TertatololMycophenolic acid may decrease the antihypertensive activities of Tertatolol.Experimental
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Mycophenolic acid.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tiaprofenic acid.Approved
TicarcillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Ticarcillin resulting in a loss in efficacy.Approved, Vet Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tiludronic acid.Approved, Vet Approved
TimololMycophenolic acid may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tixocortol.Approved
TobramycinMycophenolic acid may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TofacitinibMycophenolic acid may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Mycophenolic acid.Approved
TorasemideMycophenolic acid may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Mycophenolic acid.Approved
TranilastThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tranilast.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Mycophenolic acid.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mycophenolic acid.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mycophenolic acid.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Triamcinolone.Approved, Vet Approved
TriamtereneMycophenolic acid may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mycophenolic acid.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Triptolide.Investigational
TrovafloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Trovafloxacin.Approved, Withdrawn
TroxerutinMycophenolic acid may increase the anticoagulant activities of Troxerutin.Investigational
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Mycophenolic acid.Approved
ValaciclovirThe serum concentration of Mycophenolic acid can be increased when it is combined with Valaciclovir.Approved, Investigational
ValganciclovirThe serum concentration of Valganciclovir can be increased when it is combined with Mycophenolic acid.Approved, Investigational
ValrubicinMycophenolic acid may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Mycophenolic acid.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Mycophenolic acid.Approved
WarfarinMycophenolic acid may increase the anticoagulant activities of Warfarin.Approved
XimelagatranMycophenolic acid may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Mycophenolic acid.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Mycophenolic acid.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Mycophenolic acid.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinMycophenolic acid may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinMycophenolic acid may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Mycophenolic acid.Approved
Food Interactions
Not Available

References

Synthesis Reference

Bernard J. Abbott, John G. Whitney, "Method of preparing mycophenolic acid glucoside." U.S. Patent US4234684, issued January, 1976.

US4234684
General References
  1. Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, Taylor RS: Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Assess. 2005 May;9(21):1-179, iii-iv. [PubMed:15899149 ]
External Links
Human Metabolome Database
HMDB15159
PubChem Compound
446541
PubChem Substance
46504559
ChemSpider
393865
BindingDB
19264
ChEBI
168396
ChEMBL
CHEMBL866
Therapeutic Targets Database
DAP000784
PharmGKB
PA164748728
HET
MOA
Drugs.com
Drugs.com Drug Page
Wikipedia
Mycophenolic_acid
ATC Codes
L04AA06 — Mycophenolic acid
AHFS Codes
  • 92:00.00
PDB Entries
FDA label
Not Available
MSDS
Download (74 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0TerminatedTreatmentAllogeneic peripheral haematopoietic stem cell transplant / Neuroepithelial Tumor / Tumors, Solid1
0WithdrawnTreatmentMultiple Myeloma (MM) / Myeloma-Multiple1
1CompletedTreatmentDrug Interaction Potentiation1
1CompletedTreatmentEnd Stage Renal Disease (ESRD) / Transplantation, Kidney1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentPrimary Sjogren's Syndrome1
1Not Yet RecruitingTreatmentHaemoglobinopathies congenital / Sickle Cell Disorders / Thalassaemic disorders1
1RecruitingTreatmentAgnogenic Myeloid Metaplasia / Leukemias / Malignant Lymphomas / Smith-Magenis Syndrome1
1RecruitingTreatmentTransplantation, Liver1
1, 2CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
1, 2CompletedTreatmentGraft Versus Host Disease (GVHD) / Malignancies, Hematologic1
1, 2CompletedTreatmentMalignancies, Hematologic1
1, 2CompletedTreatmentTransplantation, Kidney1
1, 2RecruitingBasic ScienceTransplantation, Kidney1
1, 2RecruitingTreatmentAdult Living Donor Kidney Transplant Recipients / Living Kidney Donors / Transplant, Kidney1
1, 2RecruitingTreatmentScleroderma, Systemic / Severe Systemic Sclerosis1
1, 2Unknown StatusTreatmentHematologic Diseases1
2Active Not RecruitingPreventionGraft Versus Host Disease (GVHD)1
2Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas1
2CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2CompletedTreatmentNeoplasms, Malignant1
2CompletedTreatmentNephritis, Lupus1
2CompletedTreatmentTransplantation, Renal1
2RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Essential Thrombocythemia (ET) / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Juvenile Myelomonocytic Leukemia / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Polycythemia Vera (PV) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Cytopenia With Multilineage Dysplasia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2RecruitingTreatmentAcute myeloid leukaemia (in remission) / Aplastic Anaemia (AA) / Chronic Myelomonocytic Leukemia / Indolent Non-Hodgkin's Lymphomas / Leukemia Acute Myeloid Leukemia (AML) / Lymphoma, Hodgkins / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Neoplasms, Malignant / Plasma Cell Myeloma / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Ring Sideroblasts / Refractory Cytopenia With Multilineage Dysplasia / Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts1
2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
2SuspendedTreatmentCrohn's Disease (CD)1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / All / Chronic Lymphocytic Leukaemia (CLL) / CLL / Leukemia Acute Myeloid Leukemia (AML) / Leukemias / Lymphoma, Hodgkins / Malignancies, Hematologic / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL) / Plasma Cell Myeloma1
2TerminatedTreatmentLeukemias / Myelodysplastic Syndromes1
2TerminatedTreatmentMalignant Lymphomas1
2Unknown StatusTreatmentChronic Renal Insufficiency / Transplantation, Liver1
2WithdrawnTreatmentDiabetes, Diabetes Mellitus Type 11
2, 3RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
3Active Not RecruitingTreatmentUveitis, Intermediate1
3CompletedPreventionTransplantation, Kidney1
3CompletedTreatmentAutoimmune Diseases1
3CompletedTreatmentGlomerulonephritis minimal lesion1
3CompletedTreatmentKidney Diseases1
3CompletedTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
3CompletedTreatmentPancreas Transplantation / Transplantation, Kidney1
3CompletedTreatmentRejection, Transplant / Transplantation, Kidney1
3CompletedTreatmentRenal Interstitial Fibrosis1
3CompletedTreatmentTransplant, Kidney4
3CompletedTreatmentTransplant; Failure, Kidney1
3CompletedTreatmentTransplantation, Kidney2
3CompletedTreatmentTransplantation, Liver3
3CompletedTreatmentTransplantation, Renal3
3Enrolling by InvitationNot AvailableDiabetes, Diabetes Mellitus Type 1 / Islet Transplantation1
3RecruitingTreatmentChronic Kidney Disease (CKD)1
3TerminatedNot AvailableSarcoidosis, Pulmonary1
3TerminatedTreatmentGraft Versus Host Disease (GVHD)1
3TerminatedTreatmentNephritis, Lupus1
3TerminatedTreatmentSystemic Lupus Erythematosus (SLE)1
3Unknown StatusTreatmentHeart Transplant Patients1
4Active Not RecruitingPreventionInfections, Cytomegalovirus / Transplantation Infection1
4Active Not RecruitingTreatmentChronic Kidney Disease (CKD) / End Stage Renal Disease (ESRD) / Hemodialysis-dependent patients / Renal Replacement Therapies / Transplantation, Renal1
4Active Not RecruitingTreatmentCytomegalovirus / Transplantation, Kidney1
4Active Not RecruitingTreatmentTransplantation, Renal1
4CompletedNot AvailableEnd Stage Liver Diseases1
4CompletedPreventionAdverse Effects / Transplantation, Kidney1
4CompletedPreventionChronic Hepatitis C Infection1
4CompletedPreventionTransplantation, Kidney1
4CompletedSupportive CareTransplantation, Renal1
4CompletedTreatmentBK Virus Infection1
4CompletedTreatmentBioavailability / Concomitant Medication After Renal Transplantation / Drug Interactions / Immunosuppressive Medication After Renal Transplantation1
4CompletedTreatmentChronic Renal Failure (CRF)1
4CompletedTreatmentDisorder Related to Renal Transplantation / Infections, Cytomegalovirus1
4CompletedTreatmentEnd Stage Renal Disease (ESRD)1
4CompletedTreatmentEnd-Stage Renal Disease (ESRD)1
4CompletedTreatmentGastrointestinal Lesions / Signs and Symptoms, Digestive1
4CompletedTreatmentGastrointestinal Problems / Transplantation, Renal1
4CompletedTreatmentGastrointestinal Symptoms / Heart Transplantation1
4CompletedTreatmentInfections, Cytomegalovirus / Renal Transplant Failure / Transplant; Complication, Rejection1
4CompletedTreatmentKidney Transplant Recipients1
4CompletedTreatmentLiver Cirrhosis / Liver Transplant Disorder1
4CompletedTreatmentRenal Function1
4CompletedTreatmentRenal Transplanted Recipients1
4CompletedTreatmentTransplant, Kidney2
4CompletedTreatmentTransplant, Kidney / Transplantation, Kidney1
4CompletedTreatmentTransplantation, Kidney2
4CompletedTreatmentTransplantation, Liver1
4CompletedTreatmentTransplantation, Renal3
4Not Yet RecruitingTreatmentGastrointestinal Disorder, Functional / Kidney Transplant Rejection1
4Not Yet RecruitingTreatmentImmunosuppression After Renal Transplantation / Transplant, Kidney1
4RecruitingPreventionInfections, Cytomegalovirus1
4RecruitingTreatmentAntibody Mediated Rejection / End Stage Renal Disease (ESRD)1
4RecruitingTreatmentChronic Renal Failure (CRF) / Graft Failure / Kidney Transplant Rejection / Transplant; Failure, Kidney1
4RecruitingTreatmentGlomerulonephritis minimal lesion1
4RecruitingTreatmentHepatocellular,Carcinoma1
4RecruitingTreatmentImmunosuppression1
4RecruitingTreatmentImplant or Graft; Rejection1
4RecruitingTreatmentInfections, Cytomegalovirus / Transplantation Infection1
4RecruitingTreatmentKidney Transplant Rejection / Other Complications of Kidney Transplant1
4TerminatedPreventionSkin Cancers / Transplantation, Kidney1
4TerminatedPreventionTransplantation, Kidney1
4TerminatedPreventionTransplantation, Renal1
4TerminatedTreatmentTransplantation, Kidney1
4TerminatedTreatmentTransplantation, Renal2
4Unknown StatusNot AvailableTransplantation, Lung1
4Unknown StatusPreventionDiabetes / Rejection, Transplant1
4Unknown StatusPreventionKidney; Complications, Allograft1
4Unknown StatusTreatmentInfections, Cytomegalovirus1
4Unknown StatusTreatmentTransplant, Kidney1
4Unknown StatusTreatmentTransplantation, Organ1
4Unknown StatusTreatmentTransplantation, Renal1
4WithdrawnTreatmentCardiovascular Disease (CVD) / Cardiovascular Outcomes / Kidney Transplant Recipients / Transplantation, Kidney1
4WithdrawnTreatmentLiving Donor Kidney Transplants Patients1
4WithdrawnTreatmentReperfusion Injury / Transplantation, Kidney / Transplantation, Renal1
4WithdrawnTreatmentTransplantation, Liver1
Not AvailableCompletedNot AvailableGI Disturbance1
Not AvailableCompletedTreatmentArthritis / Systemic Lupus Erythematosus (SLE)1
Not AvailableCompletedTreatmentHigh Model for End-Stage Liver Disease (MELD) Score1
Not AvailableCompletedTreatmentImmunosuppression2
Not AvailableNo Longer AvailableNot AvailableDiabetes, Diabetes Mellitus Type 11
Not AvailableNot Yet RecruitingNot AvailableAcute Rejection of Renal Transplant / Biopsy Proven Acute Rejection (BPAR) / Bone Diseases / Cardiovascular Risk Factors / Graft Failure / HLA Antibody Production / Infection NOS / Mortality / Non-HLA Antibody Production / Post Transplant Diabetes Mellitus / Quality of Life1
Not AvailableRecruitingNot AvailableNephritis, Lupus1
Not AvailableRecruitingPreventionDiabetes, Diabetes Mellitus Type 11
Not AvailableRecruitingPreventionImmunosuppression / Renal Failure1
Not AvailableRecruitingTreatmentDisorder Related to Renal Transplantation / Effects of Immunosuppressant Therapy1
Not AvailableTerminatedTreatmentAcute Rejection / Transplantation, Renal1
Not AvailableTerminatedTreatmentTransplantation, Kidney1
Not AvailableTerminatedTreatmentTransplantation, Liver1
Not AvailableUnknown StatusNot AvailableUveitis1
Not AvailableUnknown StatusTreatmentMyasthenia Gravis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Tablet, delayed releaseOral180 mg
Tablet, delayed releaseOral360 mg
Tablet, delayed releaseOral180 mg/1
Tablet, delayed releaseOral360 mg/1
Prices
Unit descriptionCostUnit
Myfortic 360 mg Enteric Coated Tabs8.0USD tab
Myfortic 360 mg tablet7.69USD tablet
Myfortic 180 mg tablet3.85USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2250906 No2006-10-032017-04-10Canada
US6025391 No1997-04-102017-04-10Us
US6172107 No1997-04-102017-04-10Us
US6306900 No1998-02-272018-02-27Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)141 °CPhysProp
water solubilityInsolubleNot Available
logP2.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0355 mg/mLALOGPS
logP2.36ALOGPS
logP3.53ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)3.57ChemAxon
pKa (Strongest Basic)-4.1ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area93.06 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity85.23 m3·mol-1ChemAxon
Polarizability32.95 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9409
Blood Brain Barrier+0.5826
Caco-2 permeable-0.5583
P-glycoprotein substrateSubstrate0.8058
P-glycoprotein inhibitor INon-inhibitor0.7888
P-glycoprotein inhibitor IIInhibitor0.545
Renal organic cation transporterNon-inhibitor0.8199
CYP450 2C9 substrateNon-substrate0.8305
CYP450 2D6 substrateNon-substrate0.8575
CYP450 3A4 substrateSubstrate0.6934
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7237
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.9619
BiodegradationReady biodegradable0.5888
Rat acute toxicity2.9907 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.753
hERG inhibition (predictor II)Non-inhibitor0.6329
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-002r-0490000000-99420edc8894323b59c3
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-0009000000-b99d88ff2ddeb6977c4a
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-0149000000-ed6b854b4f9af495c8d8
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0972000000-12d0e80f109d1fa6eb11
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0950000000-2e6c3543fe3f9f4e0790
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0930000000-e7a74fbe76e7141ec5f3
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-022c-0910000000-27f7c0023a8b7e5b4d66
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-0009000000-4aba5ee4ba77899b36fb
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-0149000000-497b49ab395f3319c943
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0971000000-68634f04b665bb0e68a3
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0950000000-37f2ee0320d2ec560b93
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0f6x-0930000000-500359a3fd82c686ff99
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-006x-0900000000-6d04c3395aae26f88529
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-002r-0590000000-fe2f27357ba775714c5a
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-0009000000-8f75c9bc48b5eb019974
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-0009000000-57a06531623d00c32d13
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-002r-0490000000-700501110e03f998e99b
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-002r-0490000000-d857a6e047fc52e09e65
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-0659000000-ba96d820001d9e786c8d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0009000000-8855932a0a5c9af1f1f6
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0009000000-5eab5855829b8f8b0eea
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0pb9-0093000000-19fd59af4878ea5f1a97
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0190000000-6f584505d9b70bbffa5e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0890000000-fb7dec2fc3d23163125f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-1910000000-107f1e78387f32f7de88
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0pbc-3900000000-b1724166cac37a86cf14
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0009000000-8de82df3dfe7724905cc
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0pb9-0093000000-921ff4437b7ebfa1c724
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0190000000-51bdcbf497148c8b5520
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0890000000-c295a83b84c00d94f85f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-1910000000-92e91c6ef0f2c538121f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0pbc-3900000000-410eebeb0513756f40b0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0009000000-77bcd201c9d0349c0389
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-da3123e3ecb85f0d28ff
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-90103d288430929083b5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uxr-0090000000-3f6f29caf26c0469c12c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uxr-0090000000-7fc1bdce2eebcc00617c
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0019000000-01d925bb1f9079308d85
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0091000000-22fc916594dbab851293
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0940000000-84f4c65c2cd8b7358b78
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0593000000-1fed07ad435ca0bd7249
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0950000000-87024d6b180d1fc1c64f
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0493000000-9b99fb030e87f52cce17
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-0294000000-31d6abb5cfcd65770f2c

Taxonomy

Description
This compound belongs to the class of organic compounds known as phthalides. These are compounds containing a 3-hydrocarbylidene-2-benzofuran-1(3H)-one moiety,.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Isocoumarans
Sub Class
Isobenzofuranones
Direct Parent
Phthalides
Alternative Parents
Anisoles / Medium-chain fatty acids / Alkyl aryl ethers / Methyl-branched fatty acids / Hydroxy fatty acids / Heterocyclic fatty acids / Unsaturated fatty acids / Dicarboxylic acids and derivatives / Vinylogous acids / Lactones
show 6 more
Substituents
Phthalide / Anisole / Medium-chain fatty acid / Alkyl aryl ether / Branched fatty acid / Methyl-branched fatty acid / Heterocyclic fatty acid / Hydroxy fatty acid / Dicarboxylic acid or derivatives / Fatty acyl
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
2-benzofurans, monocarboxylic acid, phenols, gamma-lactone (CHEBI:168396 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Rna binding
Specific Function
Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore pl...
Gene Name
IMPDH2
Uniprot ID
P12268
Uniprot Name
Inosine-5'-monophosphate dehydrogenase 2
Molecular Weight
55804.495 Da
References
  1. Vannozzi F, Filipponi F, Di Paolo A, Danesi R, Urbani L, Bocci G, Catalano G, De Simone P, Mosca F, Del Tacca M: An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients. Transplant Proc. 2004 Nov;36(9):2787-90. [PubMed:15621150 ]
  2. Wang J, Zeevi A, Webber S, Girnita DM, Addonizio L, Selby R, Hutchinson IV, Burckart GJ: A novel variant L263F in human inosine 5'-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenet Genomics. 2007 Apr;17(4):283-90. [PubMed:17496727 ]
  3. Penuelas S, Noe V, Morales R, Ciudad CJ: Sensitization of human erythroleukemia K562 cells resistant to methotrexate by inhibiting IMPDH. Med Sci Monit. 2005 Jan;11(1):BR6-12. [PubMed:15614187 ]
  4. Yam P, Jensen M, Akkina R, Anderson J, Villacres MC, Wu J, Zaia JA, Yee JK: Ex vivo selection and expansion of cells based on expression of a mutated inosine monophosphate dehydrogenase 2 after HIV vector transduction: effects on lymphocytes, monocytes, and CD34+ stem cells. Mol Ther. 2006 Aug;14(2):236-44. Epub 2006 May 2. [PubMed:16647299 ]
  5. Dzidic A, Prgomet C, Mohr A, Meyer K, Bauer J, Meyer HH, Pfaffl MW: Effects of mycophenolic acid on inosine monophosphate dehydrogenase I and II mRNA expression in white blood cells and various tissues in sheep. J Vet Med A Physiol Pathol Clin Med. 2006 May;53(4):163-9. [PubMed:16629948 ]
  6. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Rna binding
Specific Function
Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore pl...
Gene Name
IMPDH1
Uniprot ID
P20839
Uniprot Name
Inosine-5'-monophosphate dehydrogenase 1
Molecular Weight
55405.365 Da
References
  1. Dzidic A, Prgomet C, Mohr A, Meyer K, Bauer J, Meyer HH, Pfaffl MW: Effects of mycophenolic acid on inosine monophosphate dehydrogenase I and II mRNA expression in white blood cells and various tissues in sheep. J Vet Med A Physiol Pathol Clin Med. 2006 May;53(4):163-9. [PubMed:16629948 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Dostalek M, Court MH, Hazarika S, Akhlaghi F: Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos. 2011 Mar;39(3):448-55. doi: 10.1124/dmd.110.036608. Epub 2010 Dec 1. [PubMed:21123165 ]
  2. Miles KK, Kessler FK, Smith PC, Ritter JK: Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9. Epub 2006 Jun 21. [PubMed:16790558 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name
UGT1A9
Uniprot ID
O60656
Uniprot Name
UDP-glucuronosyltransferase 1-9
Molecular Weight
59940.495 Da
References
  1. Dostalek M, Court MH, Hazarika S, Akhlaghi F: Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos. 2011 Mar;39(3):448-55. doi: 10.1124/dmd.110.036608. Epub 2010 Dec 1. [PubMed:21123165 ]
  2. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P: Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005 Jan;33(1):139-46. Epub 2004 Oct 6. [PubMed:15470161 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
References
  1. Dostalek M, Court MH, Hazarika S, Akhlaghi F: Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos. 2011 Mar;39(3):448-55. doi: 10.1124/dmd.110.036608. Epub 2010 Dec 1. [PubMed:21123165 ]
  2. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P: Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005 Jan;33(1):139-46. Epub 2004 Oct 6. [PubMed:15470161 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A7
Uniprot ID
Q9HAW7
Uniprot Name
UDP-glucuronosyltransferase 1-7
Molecular Weight
59818.315 Da
References
  1. Miles KK, Kessler FK, Smith PC, Ritter JK: Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9. Epub 2006 Jun 21. [PubMed:16790558 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein homodimerization activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 3 lacks trans...
Gene Name
UGT1A6
Uniprot ID
P19224
Uniprot Name
UDP-glucuronosyltransferase 1-6
Molecular Weight
60750.215 Da
References
  1. Miles KK, Kessler FK, Smith PC, Ritter JK: Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9. Epub 2006 Jun 21. [PubMed:16790558 ]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:51